•   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  •   George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    Myelodysplastic syndrome (MDS) commonly occurs before a patient develops acute leukemia, and is largely unresponsive to therapy. Two new clinical trials are entering phase 3 and may offer some hope.

    .

  •   George Lundberg, MD

    Article from the Miami Herald curated by Contributing Editor George Lundberg, MD, who notes: 

    The RenovoCath chemotherapy device permits targeted delivery of usual chemotherapy drugs directly into, and limited to, localized but inoperable pancreatic cancers. It is currently being tested in a phase 3 clinical trial.

    .

  •  

    How an Expert Would Treat His Own Glioblastoma

    With: Al Musella, DPM

    Two years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research & Information, Inc. Curious Dr. George: You direct an established foundation that supports research and information about brain tumors. What… Read more »

  •  

    What’s New in Treatment for Castrate-Resistant Prostate Cancer?

    Emma Shtivelman, PhD

    About 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already… Read more »

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Medscape has published this excellent, authoritative, comprehensive overview of ovarian cancer, which includes information on diagnosis and treatment. (Written with a physician audience in mind.)

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Rectal cancer is a subset of colon cancer but worth looking at somewhat differently because of its different location. If you wish to learn more, this presentation from Medscape is clear, detailed, unbiased, and worthy of full attention.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Small cell lung cancer is a common, particularly deadly form of lung cancer. If you wish to learn more, this authoritative encyclopedic discussion from Medscape should be very useful (written with a physician audience in mind).

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Cancer that develops in the large intestine is known as colon cancer. This comprehensive, credible, and authoritative resourse from Medscape provides in-depth and up-to-date information on this disease.

    .

    .